ÂÜÀòÂÒÂ×

Mark McDade, is a managing partner at Qiming Venture Partners USA, based in Cambridge, Mass. Before joining Qiming, he was executive vice president, chief operating officer, and an executive committee member at UCB. He led UCB’s worldwide Geographic Operations, Established Brands, Technical Operations and Business Development. Prior to UCB, Mark served as CEO and a director of PDL Biopharma, an antibody-based biopharma. Prior to PDL, he served as CEO of Signature Bioscience. Mark was founder and a director of Corixa Corporation (sold to GSK), where he served as president and chief operating officer (COO). Before Corixa, Mark was COO of Boehringer Mannheim Therapeutics, the bio-pharmaceutical division of Corange, and prior to that held several positions at Sandoz Ltd. Including business development, product management, and general management. Mark serves on the board of directors for three publicly traded biotechs: FivePrime Therapeutics (FPRX), Dermira (DERM), and Aimmune Therapeutics (AIMT). Mark received a B.A. from Dartmouth College and an MBA from the Harvard Business School.